AstraZeneca Singapore Signs MOU with Tech Partners on Innovation Projects

On 25 November 2021, AstraZeneca Singapore signed Memorandums of Understanding (MOUs) with five technology partners, in the presence of the Singapore Ministry of Health and the Swedish Ministry of Health at the Singapore-Sweden Digital Healthcare RESET Dialogue.

Together with our tech partners, namely, Respiree, OncoShot, Thermaiscan, Ubie and Hewlett Packard Enterprise (HPE), AstraZeneca Singapore aim to pilot data and artificial intelligence driven projects to drive healthcare improvement across Singapore’s healthcare ecosystem. 

The COVID-19 pandemic has exacerbated challenges in the delivery of care which has necessitated the development of innovative solutions that leverage on artificial intelligence and big data to ensure continuity of care for patients. This event brings together the Singapore Ministry of Health and the Swedish Ministry of Health to discuss the future outlook of healthcare  as we emerge from the COVID-19 pandemic, touching on topics of digital healthcare to augment our healthcare ecosystem.

The multi-party collaboration is facilitated by A.Catalyst Network, AstraZeneca’s global healthcare innovation network, and supports Singapore’s “3 Beyonds” strategy for a future-ready healthcare ecosystem. It aims to deliver innovative solutions that bring healthcare upstream (Respiree, Thermaiscan), enhance care within healthcare institutions and the broader community (Ubie, Oncoshot) and using artificial intelligence and swarm learning technologies from HPE. 

AstraZeneca’s A.Catalyst Network brings together partners across the public and private sectors to unlock the power of innovation and transform care delivery for improved patient experience and outcomes”, said Vinod Narayanan, Country President of AstraZeneca Singapore. “Facilitating such partnerships will drive improvement in the healthcare ecosystem while providing patients with access to new digital healthcare solutions that can revolutionise the management of challenging diseases such as cancer, diabetes, heart failure and respiratory diseases.

Our partnership with our tech partners has also been featured in the news:

  • Singapore Business Review (online) on 27 November 2021